Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 05TAIPEI4094, PHRMA AND TAIWAN AGREE ON COMPUTER VALIDATION

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #05TAIPEI4094.
Reference ID Created Released Classification Origin
05TAIPEI4094 2005-10-05 22:48 2011-08-23 00:00 UNCLASSIFIED American Institute Taiwan, Taipei
This record is a partial extract of the original cable. The full text of the original cable is not available.

052248Z Oct 05
UNCLAS SECTION 01 OF 02 TAIPEI 004094 
 
SIPDIS 
 
STATE FOR EAP/RSP/TC AND EB/TPP/BTA, STATE PASS AIT/W AND 
USTR, USTR FOR WINELAND AND WINTERS, USDOC FOR 
4431/ITA/MAC/AP/OPB/TAIWAN/MBMORGAN AND JDUTTON 
 
E.O. 12958: N/A 
TAGS: ECON ETRD TW
SUBJECT: PHRMA AND TAIWAN AGREE ON COMPUTER VALIDATION 
 
REF: A. TAIPEI 3807 
 
     B. TAIPEI 2078 
 
1.  Summary:  AIT and the Pharmaceutical Research 
Manufacturers Association (PhRMA), accompanied by 
representatives of Japanese and European pharmaceutical 
associations, met with Taiwan's Bureau of Food and Drug 
Analysis (BFDA) to discuss pharmaceutical validation 
requirements.  The positive tone set by the new director 
general of the BFDA and the presence of other international 
pharmaceutical associations resulted in fruitful discussions 
that essentially resolved questions of computer validation 
requirements and led to progress on finalizing the 
methodology for determining which manufacturing sites will be 
the first to be inspected.  End summary. 
 
2.  On September 13, AIT accompanied members of PhRMA, the 
Japanese Pharmaceutical Manufacturers Association (JPMA) and 
the European Federation of Pharmaceutical Industries and 
Associations (EFPIA) to meetings with BFDA,  and Bureau of 
Pharmaceutical Affairs (BOPA)(reported reftel a.)  In sharp 
contrast to PhRMA's April meeting on pharmaceutical 
validation with BFDA (reftel b), discussions this time were 
calm and productive.  Both sides were well prepared and the 
reasonableness of the new BFDA Director General Chen Shu-kong 
was a welcome relief.  Discussions focused on implementation 
of computer validation requirements (information on a 
pharmaceutical manufacturers computerized systems, training, 
and software and hardware management protocols) for 
manufacturing sites and clarifications on BFDA's method of 
calculating the Risk Priority Number (RPN) used to determine 
BFDA's inspection schedule. 
 
============================================ 
Japan and EU Weigh In on Computer Validation 
============================================ 
 
3.  In response to Dr. Chen's initial question about 
requirements for computer validation by health authorities in 
other countries, JPMA representative Kenta Goto explained 
that in order to guarentee product quality, Japan has had a 
mandatory computer validation requirement in place for many 
years.  Although Japan's laws and regulations covering 
computer validation have been subject to revision, the actual 
requirement has effectively been in place continuously since 
1993.  Malcolm Holmes, from EFPIA, informed Chen that an EU 
Directive required that all EU members must have a law 
requiring computer validation regimes in place in their 
national codes by April 2004.  After that date, if no law 
existed, the EU regulation requiring the same would take 
precedence.  Newly acceding EU states must be in compliance 
upon accession.  Holmes added that several EU regulations and 
directives have addressed the issue of computer validation 
requirements since 1991. 
 
4.  BFDA agreed to accept government issued Certificates of 
Pharmaceutical Product from the US, Japan and the EU as 
effectively complying with the Taiwan requirement for 
computer validation, but requested more information from both 
the EU and Japan about their current regulations.  Moreover, 
BFDA requested that manufacturing sites provide computer 
manuals and standard operating procedures or reference 
numbers of manuals for BFDA to review. 
 
5.  Guy Wingate, also from EFPIA and an expert on computer 
validation, responded that BFDA's over-reliance on documents 
as a means to prove the existence of good computer system 
practices was impractical.  Wingate noted that most factories 
would have thousands of computerized systems operating 
simultaneously and with constantly changing procedures, 
providing manuals or reference numbers to BFDA for each of 
them would not only be an onerous requirement, it would be of 
questionable value.  Instead, he suggested that a paragraph 
describing the structural testing regime and computer system 
lifecycle be included in the overview of manufacturing 
practices submitted by each company to BFDA.  After some 
discussion and internal debate, BFDA agreed to consider 
EFPIA's proposal. 
 
============================= 
Who Will Get Inspected First? 
============================= 
 
6.  Finally, the discussion turned to the methodology used by 
BFDA to compute the RPN.  International pharmaceutical 
manufacturers disagree with the need for BFDA to conduct 
regular inspections of international pharmaceutical 
manufacturers, believe BFDA is more interested in creating a 
cadre of experienced inspectors through unnecessary 
inspections and are concerned that the weighting of several 
of the criteria, including extra emphasis on previous records 
of recalled products, was unbalanced.  BFDA agreed to 
distinguish between voluntary and mandatory recalls in the 
determination of the RPN and to give a higher score to those 
areas with weak regulatory oversight.  BFDA also agreed to 
keep confidential the RPN of each manufacturing site. 
 
7. Comment: The patience and reasonableness of the new 
Director General of BFDA, as well as the sound preparation by 
experts from JPMA and EFPIA, were crucial to the success of 
this series of meetings.  PhRMA and the other international 
pharmaceutical associations are not pleased by the prospect 
of their manufacturing operations being inspected by BFDA. 
They view this as a time-consuming and expensive endeavor, 
with limited value in the majority of cases.  However, they 
appear to be resigned to this new requirement and can take 
heart from the fact the BFDA does not have the capacity to 
inspect more than a handful of sites each year -- their goal 
of 50 inspections in 2005 is likely to be closer to 20.  The 
outline of the agreement on computer validation requirements 
appears to be a win for the industry, but as always, the 
proof will be in the shape of the published requirements, a 
copy of which BFDA promised to provide soon.  End Comment. 
PAAL